BHC FRAUD ALERT: Jakubowitz Law is Investigating Bausch Health Companies Inc. in Connection with Potential Violations of Federal Securities Laws
NEW YORK, July 21, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Bausch Health Companies Inc. (NYSE: BHC)
To be contacted by a member of our team, fill out the form:
Further details on the investigation: The investigation focuses on whether Bausch Health issued false and/or misleading statements and/or failed to disclose information pertinent to investors concerning its 2022 earnings and guidance and its patent dispute over Xifaxan. On May 10, 2022, Bausch Health announced its first-quarter 2022 results, prompting the stock price to fall $3.50 per share. Analysts attributed the decline to concerns around the Company's spin-off of Bausch + Lomb Corporation, high debt levels, and anticipation over the Xifaxan patent decision. On July 28, 2022, the Company issued an update on the Xifaxan patent dispute case between Bausch Health and Norwich. In response to this news, market analysts downgraded Bausch Health and its stock price fell an additional $3.58 per share, representing a decline of more than 50% from its trading price just two months earlier.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
SOURCE Jakubowitz Law
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article